Renaissance Technologies LLC Trims Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Renaissance Technologies LLC decreased its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 64.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 152,300 shares of the company’s stock after selling 271,200 shares during the period. Renaissance Technologies LLC owned 0.06% of Lyell Immunopharma worth $221,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. ProShare Advisors LLC lifted its stake in shares of Lyell Immunopharma by 9.3% during the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock valued at $109,000 after buying an additional 4,170 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Lyell Immunopharma by 67.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company’s stock valued at $109,000 after buying an additional 19,718 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Lyell Immunopharma by 197.8% during the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after buying an additional 26,635 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Lyell Immunopharma during the first quarter valued at approximately $64,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Lyell Immunopharma by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock valued at $974,000 after buying an additional 38,487 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Analyst Upgrades and Downgrades

LYEL has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Monday, August 19th. Bank of America cut their price target on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, June 27th.

Lyell Immunopharma Stock Up 8.3 %

NASDAQ:LYEL opened at $1.18 on Friday. The company has a market cap of $300.83 million, a P/E ratio of -1.31 and a beta of -0.53. Lyell Immunopharma, Inc. has a fifty-two week low of $1.06 and a fifty-two week high of $3.26. The firm’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.88.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.02. Lyell Immunopharma had a negative net margin of 389,368.50% and a negative return on equity of 33.35%. The company had revenue of $0.01 million during the quarter. Research analysts forecast that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.